Special Issue "Microbial Biocatalysis, 2nd Edition"

A special issue of Catalysts (ISSN 2073-4344). This special issue belongs to the section "Biocatalysis".

Deadline for manuscript submissions: 31 December 2023 | Viewed by 614

Special Issue Editors

Jiangxi Province Key Laboratory of Mining and Metallurgy Environmental Pollution Control, School of Resource and Environmental Engineering, Jiangxi University of Science and Technology, Ganzhou 341000, China
Interests: biocatalysis and biodegradation; bioavailability of hydrophobic organic compounds; environmental stress and microbial metabolic response
Special Issues, Collections and Topics in MDPI journals
State Key Laboratory of Microbial Metabolism, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China
Interests: microbial transformation; bioprocess engineering
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Following a successful first edition, we are pleased to announce the launch of the second edition of this Special Issue, entitled "Microbial Biocatalysis, 2nd Edition".

Biocatalysis is a sustainable alternative for the chemical industry in manufacturing, monitoring, and waste management. Biocatalytic processes are performed with isolated enzymes or whole cells as biocatalysts. Whole-cell biocatalysts offer some unique advantages of cascade reactions catalyzed by multienzymes as well as a single bioredox reaction with cofactor regeneration in a single strain. Therefore, whole-cell biocatalysts are widely applied for biosynthesis/biotransformation to produce value-added chemicals as well as to achieve the complete mineralization of organic pollutants.

Biological catalytic processing using whole-cell biocatalysts includes biocatalyst engineering, bio-reaction engineering, and downstream processing. In addition to the traditional screening of microbial strains and immobilized whole-cell biocatalysts, modern genetic engineering, metabolic engineering, and synthetic biology make tailored whole-cell biocatalysts possible. At the same time, some integrated processes have been successfully applied in the catalytic processing using living whole-cell biocatalyst, such as harnessing biocompatible chemistry to interface with the microbial metabolism and using various separation techniques for in situ product removal.

The purpose of this Special Issue is to collect original research papers and reviews focusing on progress using living whole-cell biocatalysts in biosynthesis, biotransformation, and biodegradation.

Dr. Tao Pan
Dr. Zhilong Wang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Catalysts is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • whole-cell biocatalyst
  • immobilized cells
  • genetic engineering
  • metabolic engineering
  • synthetic biology
  • bio-reaction engineering
  • fermentation
  • interfacial biocatalysis
  • biocompatible chemistry
  • chemo-enzymatic cascade reaction
  • designing bioreactor
  • process optimization
  • separation engineering
  • integrated processes
  • in situ product removal
  • extractive fermentation
  • biosynthesis
  • industrial enzymes
  • antibody
  • biosurfactant
  • biopigments
  • bioflavors
  • biofuels
  • bio-based materials
  • bioactive chemicals
  • extracellular polymeric substances
  • biotransformation
  • drug intermediate
  • chiral chemical
  • value-added chemical
  • biodegradation
  • crude oil
  • aromatic hydrocarbon
  • aniline
  • plasticizer
  • pesticide
  • environmental hormone
  • microplastic
  • bio-desulfurization

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Microbial Transformation of Pimavanserin by Cunninghamella blakesleeana AS 3.970
Catalysts 2023, 13(8), 1220; https://doi.org/10.3390/catal13081220 - 17 Aug 2023
Viewed by 345
Pimavanserin is an approved selective 5-HT2A receptor inverse agonist for treating Parkinson’s disease psychosis. However, few studies on its metabolism in vitro have been investigated. In this research, eight strains of fungi are used to study the pimavanserin metabolism profiles in vitro [...] Read more.
Pimavanserin is an approved selective 5-HT2A receptor inverse agonist for treating Parkinson’s disease psychosis. However, few studies on its metabolism in vitro have been investigated. In this research, eight strains of fungi are used to study the pimavanserin metabolism profiles in vitro and six of them demonstrated positive transformation results. Factors influencing the transformation rate, like substrate concentration, culture time, initial media pH value, culture temperature, and shaking speed, were evaluated and optimized. Cunninghamella blakesleeana AS3.970 provided the best transformation rate of 30.31%, and 10 unreported metabolites were screened by LC-MS/MS. Among these metabolites, M1 is the major one and identified as 1-(4-fluorobenzyl)-3-(4-(2-hydroxy-2-methylpropoxy)benzyl)-1-(1-methylpiperidin-4-yl)urea, which is a hydroxylation product of the pimavanserin. A preliminary molecular docking simulation was performed, which indicated that M1 exhibits similar binding properties with pimavanserin and may become a potential candidate for Parkinson’s disease treatment. Full article
(This article belongs to the Special Issue Microbial Biocatalysis, 2nd Edition)
Show Figures

Graphical abstract

Back to TopTop